Literature DB >> 19220309

Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study.

F Facchinetti1, G Allais, R E Nappi, R D'Amico, L Marozio, L Bertozzi, A Ornati, C Benedetto.   

Abstract

The aim was to assess whether women suffering from migraine are at higher risk of developing hypertensive disorders in pregnancy. In a prospective cohort study, performed at antenatal clinics in three maternity units in Northern Italy, 702 normotensive women with singleton pregnancy at 11-16 weeks' gestation were enrolled. Women with a history of hypertensive disorders in pregnancy or presenting chronic hypertension were excluded. The presence of migraine was investigated according to International Headache Society criteria. The main outcome measure was the onset of hypertension in pregnancy, defined as the occurrence of either gestational hypertension or preeclampsia. Two hundred and seventy women (38.5%) were diagnosed with migraine. The majority (68.1%) suffered from migraine without aura. The risk of developing hypertensive disorders in pregnancy was higher in migraineurs (9.1%) compared with non-migraineurs (3.1%) [odds ratio (OR) adjusted for age, family history of hypertension and smoking 2.85, 95% confidence interval (CI) 1.40, 5.81]. Women with migraine also showed a trend to increased risk for low birth weight infants with respect to women without migraine (OR 1.97, 95% CI 0.98, 3.98). Women with migraine are to be considered at increased risk of developing hypertensive disorders in pregnancy. The diagnosis of primary headaches should be taken into account at antenatal examination.

Entities:  

Mesh:

Year:  2009        PMID: 19220309     DOI: 10.1111/j.1468-2982.2008.01704.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  26 in total

Review 1.  Migraine aura pathophysiology: the role of blood vessels and microembolisation.

Authors:  Turgay Dalkara; Ala Nozari; Michael A Moskowitz
Journal:  Lancet Neurol       Date:  2010-03       Impact factor: 44.182

2.  Risk of preterm delivery and hypertensive disorders of pregnancy in relation to maternal co-morbid mood and migraine disorders during pregnancy.

Authors:  Swee May Cripe; Ihunnaya O Frederick; Chunfang Qiu; Michelle A Williams
Journal:  Paediatr Perinat Epidemiol       Date:  2011-01-14       Impact factor: 3.980

Review 3.  Preeclampsia and migraine: a prediction perspective.

Authors:  Fabio Facchinetti; Alessia Sacco
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

Review 4.  Migraine in pregnancy and lactation.

Authors:  Paru S David; Juliana M Kling; Amaal J Starling
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

5.  Triptan safety during pregnancy: a Norwegian population registry study.

Authors:  Kateřina Nezvalová-Henriksen; Olav Spigset; Hedvig Nordeng
Journal:  Eur J Epidemiol       Date:  2013-07-25       Impact factor: 8.082

Review 6.  Headache and arterial hypertension.

Authors:  Cinzia Finocchi; Davide Sassos
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

7.  Trimester-specific blood pressure levels and hypertensive disorders among pregnant migraineurs.

Authors:  Michelle A Williams; B Lee Peterlin; Bizu Gelaye; Daniel A Enquobahrie; Raymond S Miller; Sheena K Aurora
Journal:  Headache       Date:  2011-07-28       Impact factor: 5.887

Review 8.  Estrogen, migraine, and vascular risk.

Authors:  Gianni Allais; Giulia Chiarle; Silvia Sinigaglia; Gisella Airola; Paola Schiapparelli; Chiara Benedetto
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

9.  Risk of placental abruption in relation to migraines and headaches.

Authors:  Sixto E Sanchez; Michelle A Williams; Percy N Pacora; Cande V Ananth; Chungfang Qiu; Sheena K Aurora; Tanya K Sorensen
Journal:  BMC Womens Health       Date:  2010-10-26       Impact factor: 2.809

Review 10.  Migraine and the risk for stroke and cardiovascular disease.

Authors:  Simona Sacco; Tobias Kurth
Journal:  Curr Cardiol Rep       Date:  2014-09       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.